Drug Trial Radar · NCT04419363
Burosumab in Children and Adolescents With X-linked Hypophosphatemia
Last checked: Nov 20, 2026Latest source record: Jun 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
57
Planned (sponsor's estimate)
Start
Mar 18, 2018
Primary completion
Mar 20, 2019
Study completion Sep 16, 2022
Sponsor
- Lead sponsor
- Bicetre HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 year, up to 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this prospective longitudinal cohort study we studied the efficacy and safety of burosumab in real-clinical practice for \<13- and \>13-years old children affected with X-linked hypophosphatemia. 57 children with XLH were switched from conventional treatment to burosumab. After 12 months we assessed the efficacy and safety of treatment with burosumab on the whole cohort and separately on the cohort of \>13-years old adolescents.
Conditions
- Rare Diseases
- X-linked Hypophosphatemia
Interventions
Burosumab InjectionDrug
Children affected with X-linked hypophosphatemia were switched from conventional therapy to burosumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Radiological changes in rachitic lesions evaluated with knee MRITime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital Bicetre
Le Kremlin-Bicêtre, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.